Richard A. Heyman - Aug 15, 2024 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
Director
Signature
/s/ Ben Hohl, by power of attorney
Stock symbol
ELVN
Transactions as of
Aug 15, 2024
Transactions value $
-$29,526
Form type
4
Date filed
8/19/2024, 07:49 PM
Previous filing
Aug 2, 2024
Next filing
Sep 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ELVN Common Stock Sale -$14.8K -650 -0.49% $22.82 131K Aug 15, 2024 Direct F1, F2
transaction ELVN Common Stock Sale -$14.7K -620 -0.47% $23.70 130K Aug 15, 2024 Direct F1, F3
holding ELVN Common Stock 37.4K Aug 15, 2024 See footnote F4
holding ELVN Common Stock 27.9K Aug 15, 2024 See footnote F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 17, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $22.36 to $23.3588. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 This transaction was executed in multiple trades at prices ranging from $23.44 to $23.77. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 The shares are held of record by the Richard A. Heyman and Anne E. Daigle Trust, dated November 1, 2016 for which the Reporting Person serves as trustee.
F5 The shares are held of record by RAHD Capital LLC for which the Reporting Person serves as a managing member.